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Abstract Osteoporosis is a well-recognized disease with
severe consequences if left untreated. Randomized con-
trolled trials are the most rigorous method for determining
the efficacy and safety of therapies. Nevertheless, ran-
domized controlled trials underrepresent the real-world
patient population and are costly in both time and money.
Modern technology has enabled researchers to use infor-
mation gathered from large health-care or medical-claims
databases to assess the practical utilization of available
therapies in appropriate patients. Observational database
studies lack randomization but, if carefully designed and
successfully completed, can provide valuable information
that complements results obtained from randomized con-
trolled trials and extends our knowledge to real-world
clinical patients. Randomized controlled trials comparing
fracture outcomes among osteoporosis therapies are diffi-
cult to perform. In this regard, large observational database
studies could be useful in identifying clinically important
differences among therapeutic options. Database studies
can also provide important information with regard to
osteoporosis prevalence, health economics, and compliance
and persistence with treatment. This article describes the
strengths and limitations of both randomized controlled
trials and observational database studies, discusses con-
siderations for observational study design, and reviews a
wealth of information generated by database studies in the
field of osteoporosis.
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Effectiveness
Osteoporosis is a worldwide health issue that affects both
men and women. Current annual rates of osteoporotic
fractures in the United States are estimated to be approxi-
mately 2 million [1]. If osteoporosis is left untreated,
increasing evidence points to a growing risk of fractures
over time [2]. The main aim of osteoporosis treatments is
to reduce fracture risk, and randomized controlled trials
(RCTs) are the gold standard for determining the efficacy
and safety of new drugs.
Over the past decade, large patient databases containing
demographic, treatment, and outcome information for a
variety of medical conditions have become common in
Europe and the United States. Osteoporosis-related frac-
tures are commonly recorded among health-care databases
[3, 4]. Observational database studies can generate valu-
able information regarding the effectiveness (i.e., efficacy
in day-to-day clinical practice) and safety of therapeutic
interventions. This type of evidence cannot replace RCT
data; however, it can expand these data to a more repre-
sentative population, identify outcomes to be further
studied in other RCTs, and examine which patient subsets
would benefit from an intervention [5, 6]. Furthermore,
these studies can provide insights into osteoporosis prev-
alence, the socioeconomic costs associated with fracture,
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and compliance and persistence with treatment. Both RCT
and observational database study designs are susceptible to
particular bias; therefore, thorough analysis of the advan-
tages and limitations associated with each particular study
is needed to interpret the totality of evidence.
Strengths and Limitations of RCTs and Observational
Database Studies
RCTs are designed to minimize bias by selecting narrow
and well-defined study populations, as equal as possible
with respect to characteristics that may impact on the
outcome variables. Participants are randomly assigned to
treatment and control groups, ensuring that differences
observed in clinical outcomes can be genuinely attributed
to treatment assignment [6, 7]. Additionally, the design of
RCTs maximizes patient compliance by ensuring accurate
and consistent use of treatment medication through strict
protocols and close follow-up [7].
The strict patient inclusion and exclusion criteria of RCTs,
however, can limit their ability to provide results that apply to
patients seen in day-to-day clinical practice. Specific patient
groups included for RCTs might not fully represent those
clinical populations for whom the tested drug will eventually
be used. Dowd et al. [8] tested this hypothesis by evaluating
120 newly diagnosed osteoporotic female patients with
regard to their eligibility for four ongoing RCTs. Although
physicians determined all of the 120 patients to be candidates
for therapy, only 3–21% were eligible to participate in the
individual RCTs. The most common reasons for patient
exclusion were comorbid illness (60%), concomitant medi-
cations (60%), high disease severity (19%), and age (36%)
[8]. In the clinical practice setting, comorbid illness, con-
comitant medications, and severe disease are realities in the
vast majority of patients with osteoporosis. In general,
patients included in RCTs tend to be less sick, younger, and
more likely compliant with therapy, all of which may over-
state the effect of a new drug should it be introduced in the
total patient population. As such, it is important to investigate
how therapies impact patients in the real world. In addition,
as a result of high costs and difficulties in recruiting eligible
patients, RCTs often have a short duration and modest
sample size. This means they can be underpowered and
unable to detect differences in infrequent clinical outcomes
that might be captured in a larger patient population [6].
Furthermore, many patients are simply adverse to the pros-
pect of being randomly selected to participate in a trial, and
those who do volunteer may be ‘‘healthier’’ at baseline
compared with those unwilling to volunteer, resulting in
better outcomes or fewer adverse events [9].
Observational database studies are able to use large
unselected patient populations, many of which would be
excluded from RCTs, and often can capture data for longer
periods, therefore evaluating the long-term effects of
therapy, such as the occurrence of rare but perhaps
important events [10]. Large database studies can often be
used to assess different therapies when head-to-head RCTs
are unavailable as a result of elevated costs and large
numbers of patients required to participate [7, 11, 12].
In addition to evaluating effectiveness, observational
database studies can estimate real-world compliance and
persistence with treatment [13, 14]. This is particularly
important for outcomes in osteoporosis because it has been
shown that treatment discontinuation is most likely to
occur within the first year of therapy [3, 4, 15]. Further-
more, database studies can evaluate the rate of fracture
incidence in different populations [16], provide insight into
secular changes in fracture incidence [17, 18], and assess
costs and health-related quality-of-life outcomes associated
with osteoporotic fractures [19].
However, the conclusions drawn from observational
database studies also have limitations. The absence of ran-
domization may cause differences in baseline characteristics
between study populations, which is known as ‘‘selection
bias’’ and could, therefore, compromise the validity of the
data. If the different characteristics are related to the mea-
sured outcomes, they are referred to as ‘‘confounders’’ and
lead to difficulties in determining causality of an observed
outcome [6, 7, 12]. Confounding factors include severity of
the disease/condition, risk factors, and indications for treat-
ment [7]. Although selection bias may be controlled for and
reduced, the impact of bias related to possible known and
unknown confounding factors that are not contained in the
database, such as body mass index, bone mineral density
(BMD), and family history of fracture or prior fracture,
cannot be estimated [6, 12]. Other limitations of observa-
tional database studies include the possibility of underre-
porting and incorrect coding and, in some studies, the
inability to validate data through chart review [7, 12].
Regarding osteoporosis, an important limitation of data-
bases is that only a minority of vertebral fractures will be
captured since databases do not provide information about
morphometric vertebral fractures.
Designing Observational Database Studies
The validity of conclusions drawn from observational data
analysis depends on carefully designed evaluation meth-
odology [7, 12, 20]. One should be certain that the database
being studied is sufficiently large to yield the statistical
power needed to identify clinically meaningful differences
in the outcomes and that the outcomes can be determined
from the information available in the database. Internal
validity should be maximized by using study populations
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that are as similar as possible, and evaluation of possible
confounders should always be included [6, 7]. Although
selection bias cannot be entirely eliminated, there are
analytical methods to control and reduce this problem.
Confounding factors should be controlled by using multi-
variable adjustment, and the significance and validity of
outcomes should be verified by performing sensitivity
analyses. In addition, propensity score analysis can statis-
tically adjust for possible selection bias [6, 21]. Under-
standing what information is accessible within a database
and what additional variables are excluded is vital in order
to recognize the limitations of any observational database
study. Furthermore, accuracy and completeness of the
information entered in the database are of great importance
to allow valid interpretations and comparisons between
studies [22].
Comparing Results from RCTs and Observational
Database Studies
Similarities between RCT and observational study data
have been identified in several studies for a range of
treatments, including cardiology and tuberculosis therapies,
as well as surgical interventions [23–26]. However, it is not
always the case that RCTs and database studies report
similar results. Reasons for discrepancies include different
patient populations and therapeutic regimens being evalu-
ated, possible selection bias, inadequate statistical power,
and differences in patient follow-up [27]. Additionally,
deficiencies in clearly stating patient characteristics (e.g.,
inclusion and exclusion criteria, demographics), details of
treatment, assessment of possible confounders, and dura-
tion of follow-up can result in data discrepancies between
RCTs and database studies [22].
Observational Database Studies in Osteoporosis
Secular Trends
Jaglal et al. [17] studied the time trends in BMD testing for
osteoporosis, prescriptions for antiresorptive therapies, and
fracture incidence in the Ontario Medicare database
1992–2003. This study has provided important information
on the impact of management efforts to reduce osteoporotic
fractures in a real-world setting. From 1992 to 2001, the
number of BMD tests increased 10-fold, and from 1996 to
2003 the number of prescriptions for antiresorptive thera-
pies increased 18-fold. It was also found that there was a
decrease in the incidence of hip and wrist fractures, with a
population projection for 2001–2005 suggesting a down-
ward trend in fracture rates [17].
A recent observational study from Switzerland revealed
a significant decrease in age-adjusted incidence of osteo-
porotic fractures in women but not in men [18]. Although
observational studies do not provide evidence for causal
relationships, these findings suggest the decline in fracture
rates might be due to increased osteoporosis awareness and
treatment.
Costs of Treatment and Quality-of-Life Associated
with Osteoporotic Fracture
The costs of osteoporosis can be astounding. Estimates
have suggested that total annual osteoporotic fracture costs
in the United States alone are nearly $17 billion [1].
Increased osteoporosis diagnosis and treatment can have a
considerable impact on health-care management. A popu-
lation-based analysis estimated that the BMD testing of an
additional 1 million older women in the United States
would result in the new prescription of an osteoporosis
treatment in 440,000 women and prevention of more than
35,000 fractures, allowing for Medicare cost savings of
almost $78 million [28]. A study in Sweden assessed the
costs and quality-of-life associated with vertebral, hip, and
Colles fractures 1 year post-fracture, providing information
regarding annual inpatient and outpatient costs [19]. It was
shown that although hip fractures were still associated with
the highest medical costs, vertebral fractures were associ-
ated with a lower quality of life than previously estimated
[19]. The design of the Swedish study by Borgstro¨m et al.
[19] was the foundation of an international observational
study, the International Costs and Utilities Related to
Osteoporotic Fractures Study (ICUROS) [29], which is
currently being conducted in order to help understand the
global cost implications of osteoporosis.
Compliance and Persistence
Several large database studies have provided important
insight into real-world patient behavior and osteoporosis
medication adherence. Downey et al. [3] evaluated data
from a large national, managed-care administrative claims
database from four different regions in the United States.
Twelve-month adherence rates (defined by a medication
possession ratio calculated as total days of therapy for
medication dispensed/365 days of study follow-up) were
found to be 54–61% for women receiving antiresorptive
therapy [3]. Persistence rates (defined as continuous therapy
on the same drug for each month over the entire study period)
were found to be 16–21% [3]. Similar rates were observed in
another database study of over 12,000 patients who initiated
treatment with either alendronate or risedronate [15]. Other
studies have suggested that patient preference for therapy
might have a beneficial effect on compliant behavior and
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that preference is greatly dependent on drug efficacy and
safety [30–32].
Data from the General Practice Research Database in the
United Kingdom demonstrated an inverse relation between
compliance and risk of osteoporotic and hip/femur fractures
[33]. Patients in this study had a 22% lower risk of hip/
femur fractures during current use of a bisphosphonate
compared with periods of past use. Claims data from two
large U.S. databases, representing a geographically diverse
population, also showed that patients adherent to therapy
have lower fracture rates, with a relative risk (RR) reduction
of 20–40% depending on the fracture site [13]. In a database
analysis of all bisphosphonate prescriptions written in
Belgium, the RR reduction for hip fracture was as much as
60% (hazard ratio [HR] = 0.40, 95% confidence interval
[CI] 0.36–0.46, P \ 0.0001) [34]. For each 1% decrease of
the medication possession ratio, the risk of hip fracture in
this study increased by 0.4%. Another claims database
analysis of postmenopausal women with osteoporosis
reported that patients persistent with therapy were 26% less
likely to have a fracture diagnosis claim than those who
were nonpersistent (HR = 0.74, 95% CI 0.55–0.99,
P = 0.45) [35]. In this regard, observational database
studies can help find solutions for enhancing compliance
and persistence by providing insight into why patients
might not comply or persist with therapy [3, 36, 37].
In recent years, monthly regimens of bisphosphonates
have been developed with the aim of increasing compli-
ance and persistence when compared with daily or weekly
regimens. A recent primary-care database study conducted
in France using 2007 medical claims data examined this
hypothesis [38]. Analyses were performed on data from
2,990 women receiving either weekly bisphosphonates
(581 alendronate and 1,408 risedronate) or monthly therapy
(1,001 ibandronate). Compliance (defined as a medication
possession ratio calculated as the duration of all filled
prescriptions/follow-up period) and persistence (defined as
time from initiation of therapy to discontinuation, with
prespecified permissible gaps) were both superior in the
monthly treatment group. Twelve-month persistence rates
were 47.5% for monthly ibandronate and 30.4% for weekly
bisphosphonates. Compliance was 84.5% in the monthly
cohort compared with 79.4% in the weekly cohort. An
important strength of this study was its attention to the
effects of potential confounds. A propensity score was
constructed, including all demographic, clinical, and
treatment variables recorded in the database, and used in
the multivariate logistic regression analysis. Although
patients receiving monthly ibandronate were younger, were
less likely to have had an osteoporotic fracture, more fre-
quently received multiple comedications, and were less
likely to have rheumatoid arthritis, dosing frequency
remained a significant independent determinant of both
compliance and persistence after these variables were taken
into account. After this statistical adjustment, women from
the monthly cohort were 37% less likely to be nonpersis-
tent and had a 5% higher mean medication possession ratio
than women receiving the weekly dosing regimens. A
potential confound that could not be taken into account in
the analysis is that the medication (i.e., ibandronate vs.
risedronate or alendronate) was confounded with the dos-
ing frequency (i.e., monthly vs. weekly treatment, respec-
tively), making it difficult to attribute superior compliance
and persistence to the dosing frequency rather than an
unmeasured variable related to the medication itself.
Although this study supported the association between
superior compliance and persistence with a lower dosing
frequency, another recent study did not support this rela-
tionship. Using the IMS longitudinal prescription database,
which contains information on prescription drugs and
represents 49% of the total retail pharmacy prescriptions
dispensed in the United States, Gold et al. [39] found that
compliance, persistence, and cumulative drug availability
were not superior for monthly ibandronate compared with
weekly risedronate dosing regimens. Compliance (defined
as the mean medication possession ratio), persistence
(calculated as the days until a gap of [90 days between
prescriptions occurred), and cumulative drug availability
(calculated as the ratio of drug supply and the days between
the first fill date and the end of the study) were evaluated
over 12 months among three cohorts: the overall sample,
patients new to osteoporosis therapy, and patients receiving
therapy in the 12 months after initial market availability for
each drug. The three cohorts were created as a means of
addressing a potential bias which could have been intro-
duced because of differences in when the two therapies
were introduced to the market, i.e., differences in the total
number of patients on each therapy as well as in the
number of patients new to therapy. Patient age and gender
were included as covariates in the analyses. As with the
previously described study, medication was confounded
with dosing frequency.
At 12 months, persistence, compliance, and cumulative
drug availability for the overall sample were significantly
higher with weekly risedronate compared to monthly
ibandronate. There were no significant differences in
compliance for patients new to osteoporosis therapy and
for patients new to therapy after initial market availability.
Persistence was significantly longer for weekly risedronate
than for monthly ibandronate for all three cohorts, and
cumulative drug availability was also superior for the
weekly regimen compared to the monthly dosing regimen
for all three cohorts. These data suggest that the effect of
factors other than dosing frequency needs to be explored to
elucidate differences in compliance and persistence among
users of osteoporosis therapy.
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Safety and Tolerability
To date, few clinical studies have been conducted regard-
ing the long-term safety and tolerability of oral bisphos-
phonates; however, those that have been published indicate
that alendronate and risedronate are well tolerated during
extended use [40, 41]. Observational databases can be a
resource for determining factors influencing tolerability
and long-term safety. A recent RCT of postmenopausal
women with osteoporosis reported a higher risk of atrial
fibrillation in women treated with zoledronic acid than in
placebo patients [42]. Since then, case–control studies have
been undertaken to assess the association between atrial
fibrillation and the use of bisphosphonates for osteoporosis.
Although one of these studies reported the use of alendronate
to be associated with an increased risk of atrial fibrillation
[43], another report found no evidence that either etidronate
or alendronate use increased such risk [44]. To minimize the
possibility of confounding, both studies adjusted for
important risk factors for atrial fibrillation and used stratifi-
cation by risk factors. Despite these measures, in the study
by Heckbert et al. [43] the number of alendronate users
was considerably small (case patients n = 47 and control
patients n = 40), whereas the study by Sørensen et al. [44]
had a much larger sample size for bisphosphonate exposure
(case patients n = 724 and control patients n = 3,138). It
should be taken into account that recording of events such as
atrial fibrillation is not always robust in either RCTs or
observational databases.
In order to further determine the risk of atrial fibrillation
resulting from bisphosphonate use, a prospective database
study of over 47,000 patients was conducted [45]. Data
from two sources comprised this study: an ongoing registry
of patients who underwent coronary angiography and the
Intermountain Healthcare health plans database. No
increased risk of atrial fibrillation was found in the bis-
phosphonate-treated group from either database. Patients in
both databases using bisphosphonates were found to be
older and more likely to have cardiovascular disease
however; and the authors posit that this might account for
the increased arrhythmia risk reported in other trials.
Recent studies have reported that long-term alendronate
use was common among patients with subtrochanteric or
proximal diaphyseal femur fractures, which has led to
questions about whether these fractures could be the result
of excessive suppression of bone turnover. A register-based
matched cohort study in patients with prior non-hip frac-
tures was conducted in order to test the hypothesis that the
increase in the risk of subsequent atypical femur fractures
in patients treated with alendronate exceeded their risk of
typical osteoporotic hip fractures [46]. After adjusting for
comorbidity and comedications, there were no significant
differences in subtrochanteric or diaphyseal fracture
between the alendronate and untreated cohorts. Further-
more, in the small number of patients (n = 178) who
received long-term alendronate treatment ([6 years) and
were highly compliant (medication possession ratio
[80%), no differences were observed in the ratio between
hip and subtrochanteric/diaphyseal femur fractures
between the two cohorts. A total of 10% of fractures in the
alendronate cohort were diaphyseal or subtrochanteric vs.
12.5% in the control cohort. Although these findings sup-
port the conclusion that these fractures are likely conse-
quences of osteoporosis, additional research in a larger
cohort of long-term bisphosphonate users is warranted.
Specifically, the authors note that this study was not able to
provide information specific to transverse subtrochanteric
fractures, and radiological and clinical review studies may
be able to provide useful information in the future. It
should also be noted that access to X-rays is not possible in
most observational studies.
Recent reports in the United States as well as in Europe
and Japan have linked esophageal cancer with oral bis-
phosphonate use [47]. Some of these patients have had
Barrett esophagus, a precursor of esophageal adenocarci-
noma. Safety studies are needed to evaluate the link
between oral bisphosphonates and esophageal cancer, but
at present, patients with Barrett esophagus should not be
prescribed oral bisphosphonates.
Comparison of Osteoporosis Treatments
An observational database study by Watts et al. [48] used a
proprietary administrative claims database to identify
managed-care members who received a new prescription
for risedronate (6-month analysis n = 1,000 and 12-month
analysis n = 652), alendronate (6-month analysis n =
5,307 and 12-month analysis n = 3,716), or nasal calcitonin
(6-month analysis n = 774 and 12-month analysis
n = 656). Patient records were analyzed for the incidence
of nonvertebral fractures in the first 6 and 12 months fol-
lowing initiation of treatment. Alendronate and risedronate
patients were similar with respect to overall health status,
whereas nasal-calcitonin patients had more hospitalizations,
physician visits, and concomitant medications, and a higher
prior fragility fracture rate. Effectiveness assessments were
limited to nonvertebral fractures because the incidence of
vertebral fractures was not captured in the administrative
claims database. After adjusting for parameters such as age,
sex, prior fragility fracture, hormone therapy use, and
number of concomitant medications, it was shown that
12 months after treatment initiation nonvertebral frac-
ture risk was reduced by 59% for patients treated with
risedronate vs. alendronate users (RR = 0.41, 95% CI
0.18–0.94, P = 0.04) and by 75% for patients receiving
risedronate compared with calcitonin (RR = 0.25, 95% CI
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0.10–0.64, P \ 0.01). These results support and comple-
ment findings observed with individual bisphosphonates in
independent RCTs (Fig. 1) [48–50]. In a post hoc analysis,
risedronate demonstrated a significant reduction in non-
vertebral fracture risk at as early as 6 months (66%,
P = 0.048), and at 12 months the risk of nonvertebral
fracture was reduced by 74% (P = 0.001) [50]. A post hoc
analysis from the alendronate trials demonstrated a signif-
icant reduction in the risk of nonvertebral fracture (26%,
P = 0.011) at 24 months [49]. The RCTs used BMD or
fracture history criteria to identify patients with osteopo-
rosis eligible for the study, whereas the observational
study included patients receiving new prescriptions for a
bisphosphonate or calcitonin without laboratory diagnostic
data confirmation. Nevertheless, results from the observa-
tional database study were comparable to those demon-
strated by each bisphosphonate in their respective clinical
trials.
The results reported by Watts et al. [48], however,
contrast with findings from a recent observational database
study evaluating the relative effectiveness of alendronate,
risedronate, raloxifene, and calcitonin in preventing non-
vertebral fractures [51]. Alendronate and risedronate
recipients were similar with regard to overall health status,
and differences between raloxifene or calcitonin users and
alendronate recipients were adjusted for. The study dem-
onstrated that within 12 months of treatment initiation the
differences in nonvertebral fracture risk between new
recipients of risedronate (n = 8,718) or raloxifene
(n = 5,038) and new alendronate users (n = 21,007) were
small. New recipients of nasal calcitonin (n = 8,372) were
at higher risk of nonvertebral fracture compared with
alendronate recipients (adjusted HR = 1.40, 95% CI
1.20–1.63, P \ 0.001). Similar results were reported for
the analysis 24 months after treatment initiation [51].
Methodological differences in the design of both of
these studies, such as the doses of bisphosphonates used
and the nonvertebral fracture sites included in the analyses,
may partially explain data discrepancies.
Head-to-Head Observational Studies of Approved
Bisphosphonates
The Risedronate and Alendronate (REAL) observational
database study [52] recently compared nonvertebral- and
hip-fracture risk between two approved bisphosphonates.
Although evidence-based consensus guidelines recommend
bisphosphonates as first-line treatment for osteoporosis
because of their effective prevention of vertebral and, in
some cases, nonvertebral fractures, lack of head-to-head
comparative trials has precluded the development of rec-
ommendations to help select specific individual treatments
[53]. A previous head-to-head comparison between
alendronate and risedronate used BMD as a surrogate
marker of fracture risk prevention, but the study did not
consider fracture reduction as an end point [54]. The REAL
study has provided an opportunity to compare alendronate
and risedronate and evaluate their effectiveness in fracture-
risk prevention in a large, clinically relevant patient
population.
The REAL study evaluated health-care utilization
records from 101 health plans in 34 U.S. states. Subjects
included women aged C65 years who were newly treated
with once-weekly risedronate (35 mg) or alendronate (35
or 70 mg). The 12,215 risedronate users were followed for
a mean of 226 days, with 63% completing 12 months of
evaluation. The 21,615 alendronate users (8% taking
35 mg and 92% taking 70 mg) were followed for a mean of
238 days, with 67% completing 12 months of evaluation.
Statistically significantly, risedronate users were older,
used more concomitant medications (including more glu-
cocorticoids), and had comorbid rheumatoid arthritis
(P B 0.01) compared with alendronate users. This suggests
a possible higher pretreatment risk for subsequent fracture
among patients treated with risedronate. Conversely,
risedronate users had greater previous use of calcitonin or
raloxifene, which may contribute to a decreased fracture
risk. During the 6- and 12-month historical periods before
bisphosphonate initiation, the clinical diagnosis of nonver-
tebral fracture was similar between subsequent risedronate
and alendronate users. However, previous hip fracture had
occurred more frequently among patients later prescribed
risedronate (P \ 0.05). This would suggest a higher pre-
treatment risk for subsequent fracture among patients trea-
ted with risedronate.
Cumulative fracture incidence at 6 and 12 months was
significantly lower with risedronate compared to alendronate
for all nonvertebral and hip fractures (P B 0.05) [52].
Fig. 1 Nonvertebral fractures in pooled randomized controlled trials
(RCTs) and observational database studies. This comparison of
previously published data on risk reduction in nonvertebral fractures
includes outcomes in RCTs and observational data for two bisphos-
phonates. Observational data are based on Watts et al. [48]. RCT data
are based on Black et al. [49] for alendronate and Harrington et al.
[50] for risedronate
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Nonvertebral fracture incidence with risedronate treatment
was 19% lower after 6 months and 18% lower after
12 months compared with alendronate. Hip-fracture inci-
dence with risedronate treatment was 46% lower after
6 months and 43% lower after 12 months compared with
alendronate therapy.
One of the strengths of the REAL study was its rigorous
sensitivity analysis, which involved an intent-to-treat group
analysis, a propensity analysis, a change in inclusion cri-
teria for the study population, and a change in inclusion
criteria for the study outcome. Significant differences in
nonvertebral- and hip-fracture incidence occurred at
6 months and persisted at 12 months after the various
sensitivity analyses. Also, excluding the small minority of
patients treated with 35 mg alendronate, outcomes after
sensitivity analyses were within the CIs of the primary
analyses. Nevertheless, it should be noted that the two
patient cohorts were dissimilar with regard to demo-
graphics and baseline characteristics, and the effect of
these differences in the observed treatment outcomes is
unknown.
These data are in agreement with the results reported by
Watts et al. [48] and seem to complement previous findings
from independent RCTs with each individual bisphospho-
nate [55–59].
The Risedronate and Alendronate Intervention over
Three Years (REALITY) trial used similar methods in a
different population to determine differences in clinical
fractures between weekly risedronate and alendronate users
[60]. This study did not support REAL’s findings of sig-
nificant differences in fracture-risk reduction between the
two treatments. Using claims data from a U.S. health-care
organization that covered over 20 million people in seven
census regions, 19,063 women were identified who were
aged C65 years and who filled new prescriptions for weekly
alendronate (n = 12,956) or risedronate (n = 6,107). Sig-
nificantly more risedronate users were aged C75 years,
used glucocorticoids, had comorbid diabetes, and were
more likely to have had a BMD test compared with
alendronate users, suggesting a possible higher pretreatment
risk for subsequent fracture among patients treated with
risedronate. Significant attrition in both cohorts occurred, in
large part due to the exclusion of patients for nonadherence
(defined by a[15-day gap after the end of one prescription
before the next prescription was filled). At 1 and 3 years,
only 22% and 3% of the original cohort remained,
respectively.
No significant differences were found between risedronate
and alendronate users at 1 year in clinical vertebral or all
nonvertebral fracture risk. Although the absolute difference
in hip-fracture rate between the two treatments was small
(approximately five fractures per 1,000 person-years), the
adjusted relative rate of hip fracture among risedronate users
was higher (RR = 1.77, 95% CI 1.15–2.74, P = 0.01)
compared with alendronate users.
Although the patient cohorts in both the REAL and the
REALITY studies were similar at baseline, because of the
exclusion of substantial numbers of patients due to non-
adherence in the REALITY study, patient groups were
likely to not be comparable at the time of the 1-year
analysis, which could partially explain the discrepant
results.
The first head-to-head observational claims data-
base study comparing monthly ibandronate with weekly
risedronate and alendronate, the Evaluation of Ibandronate
Efficacy (VIBE) study, used eligibility and pharmacy and
medical claims data from two large databases comprising
almost 90 million people [61]. Women were included in
the study if they were aged C45 years and were newly
prescribed monthly oral ibandronate or weekly oral
bisphosphonates (alendronate 35 or 70 mg, risedronate
35 mg). The primary analysis included 64,182 patients
(n = 7,345 monthly ibandronate and n = 56,837 weekly
bisphosphonate) adherent for treatment during the first
90 days from the index date (a 30-day refill gap defined
nonpersistence for weekly therapy, a 45-day gap was used
for monthly therapy). The secondary analysis included all
patients (n = 91,598) who initiated bisphosphonate treat-
ment regardless of adherence. Sensitivity analyses assessed
the effects of potential confounding variables including
age; use of other osteoporosis, glucocorticoid, or gastro-
intestinal medications; and fracture history. Monthly
ibandronate patients had significantly more concomitant
medications and were more likely to have received
gastrointestinal medications and glucocorticoids in the
6-month preindex period.
After the 12-month observational period, the risks of
hip, nonvertebral, and any clinical fracture were not sig-
nificantly different between the two treatment groups
(monthly vs. weekly bisphosphonates) among adherent
patients. Monthly ibandronate patients had a significantly
lower risk of vertebral fracture than weekly bisphosphonate
patients (adjusted RR = 0.36, 95% CI 0.18–0.75,
P = 0.006). When all patients were included in the anal-
ysis, the RRs of any type of fracture were not significantly
different between the two treatment groups. The results of
the sensitivity analyses were generally consistent with the
primary analysis.
The 12-month cumulative nonvertebral fracture inci-
dences reported in the REAL, REALITY, and VIBE
observational studies are illustrated in Fig. 2.
As fracture reduction is not likely to be immediate fol-
lowing the initiation of bisphosphonate therapy, a limita-
tion common to the REAL, REALITY, and VIBE studies is
the uncertainty of whether differences in baseline fracture
risk between treatment groups could account for the
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observed results. A recent observational study addressed
this key limitation [62]. Administrative billing data were
used to follow three cohorts of U.S. women prescribed
alendronate 70 mg/week, risedronate 35 mg/week, or
ibandronate 150 mg/month, aged C65 years, after initiating
either alendronate, risedronate, or ibandronate (n =
210,144). Within each cohort, baseline fracture risk was
defined by the initial 3-month period after starting therapy.
After 3 months of follow-up, fracture incidence was calcu-
lated for the subsequent 12 months of therapy relative to
these baselines.
At initiation of bisphosphonate use, the ibandronate
cohort was younger and had fewer prior fractures than
either the risedronate or alendronate cohort, which suggests
a lower pretreatment risk for subsequent fracture. Consis-
tent with these observations, during the 3 months after
starting therapy, the baseline incidence of hip fractures was
higher in the risedronate (0.90 per 100 person-years) and
alendronate (0.77 per 100 person-years) cohorts than in the
ibandronate cohort (0.64 per 100 person-years). When
compared to the baseline incidence, the subsequent
12-month fracture incidence was significantly lower in both
the alendronate cohort (18% lower at hip, 28% at nonver-
tebral sites, and 57% at vertebral sites) and the risedronate
cohort (27% lower at hip, 21% at nonvertebral sites, and
54% at vertebral sites). Fracture incidence in the ibandro-
nate cohort was 31% lower at vertebral sites only.
Teriparatide: Effectiveness, Safety, and Persistence
The Direct Analysis of Nonvertebral Fractures in the
Community Experience (DANCE) study is an ongoing,
prospective, cohort trial that was designed to examine the
long-term effectiveness, safety, and tolerability of teri-
paratide (parathyroid hormone 1–34). The study will also
capture data on the reasons for initiating teriparatide ther-
apy and on persistence with treatment [63]. Patients will be
followed through a course of therapy for up to 24 months
and for an additional 24 months after treatment discontin-
uation. This study will provide the opportunity to examine
the effect of prior and/or concomitant use of other bone-
active agents on teriparatide effectiveness at decreasing the
occurrence of new nonvertebral fractures. The study pop-
ulation (approximately 4,000 patients) is heterogeneous
and includes patients with comorbidities and severe osteo-
porosis. Data generated by DANCE will be a valuable
addition to the already published data on teriparatide. In
fact, recent information retrieved from DANCE indicated
that the most frequent reasons for physicians to prescribe
teriparatide therapy include very low BMD, previous self-
reported osteoporotic fracture, general frailty, advanced
age, propensity to fall, family history of osteoporotic
fractures, and intolerance or inadequate response to other
osteoporosis therapies [64]. In addition, it was estimated
that approximately 70% of patients are persistent with
teriparatide therapy at 12 months and that persistence was
not significantly affected by age, comorbidity, or baseline
osteoporosis severity [65]. Nevertheless, the high persis-
tence observed with teriparatide may not be representative
of a real-world setting because DANCE has a prospective
cohort design, in which the patients are followed through
the course of therapy.
Incorporating Observational Data into Clinical Practice
Observational studies have provided insights into many
aspects of osteoporosis and have advanced our knowledge
of its epidemiology, patient compliance and persistence
with treatment, long-term safety and tolerability of thera-
pies, and costs and quality of life associated with osteo-
porotic fractures. Observational studies can also provide
additional data on the effectiveness of osteoporosis thera-
pies, complementing findings from RCTs and generalizing
RCT results to broader patient populations. Analyzing the
strengths and limitations associated with each particular
study and study type will help to interpret outcomes and
their validity. Additional observational database studies
comparing treatment effects may be helpful in under-
standing real-world differences among osteoporosis thera-
pies. Reproducibility of the results, using standardized
methodologies, should increase the trust and importance
given to data from observational studies.
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